OneSource Pharma shares surge over 3% after partner gets approval for Semaglutide injection

Aman Shukla — Wed, 29 Apr 2026 04:23:20 +0000

Shares of OneSource Specialty Pharma Limited climbed over 3% in early trade after its strategic partner Dr. Reddy’s Laboratories received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. The development is being seen as a positive trigger for OneSource, given its role as the contract development and manufacturing (CDMO) partner for the product.

The approval allows Dr. Reddy’s to move ahead with the commercial rollout of Semaglutide Injection in Canada, a market witnessing strong demand for GLP-1-based therapies used in diabetes and weight management. For OneSource Specialty Pharma, this milestone marks a transition from development-stage collaboration to potential commercial manufacturing, which is expected to drive revenue visibility going forward.

Under the partnership, OneSource provides scale-up and manufacturing support from its US FDA-approved flagship facility in Bengaluru. As commercial supplies begin, the company is likely to benefit through manufacturing revenues tied to production volumes. This strengthens its positioning in the high-growth peptide therapeutics segment, where global demand continues to rise.

Management highlighted that the approval reinforces the collaboration between the two companies, combining Dr. Reddy’s expertise in peptide development with OneSource’s manufacturing capabilities. The company also indicated that this progress could support long-term growth through sustained commercial supply agreements.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

OneSource Pharma | Business Upturn

OneSource Pharma shares surge over 3% after partner gets approval for Semaglutide injection